Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery

Michael Gorin, Obi Ekwenna, Mark S. Soloway, Gaetano Ciancio

Research output: Contribution to journalArticle

Abstract

Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.

Original languageEnglish (US)
JournalUrology
Volume79
Issue number2
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Nephrons
Tumor Burden
Renal Cell Carcinoma
Nephrectomy
Biopsy
sunitinib
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. / Gorin, Michael; Ekwenna, Obi; Soloway, Mark S.; Ciancio, Gaetano.

In: Urology, Vol. 79, No. 2, 01.02.2012.

Research output: Contribution to journalArticle

Gorin, Michael ; Ekwenna, Obi ; Soloway, Mark S. ; Ciancio, Gaetano. / Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. In: Urology. 2012 ; Vol. 79, No. 2.
@article{4b5d16b5543c480c9f1ccacd110d0fb3,
title = "Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery",
abstract = "Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.",
author = "Michael Gorin and Obi Ekwenna and Soloway, {Mark S.} and Gaetano Ciancio",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.urology.2011.04.018",
language = "English (US)",
volume = "79",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery

AU - Gorin, Michael

AU - Ekwenna, Obi

AU - Soloway, Mark S.

AU - Ciancio, Gaetano

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.

AB - Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.

UR - http://www.scopus.com/inward/record.url?scp=84856698843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856698843&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2011.04.018

DO - 10.1016/j.urology.2011.04.018

M3 - Article

VL - 79

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -